Fibrin D-dimer and β-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation: Effects of introducing ultra- low-dose warfarin and aspirin

Circulation

Volumn 94, Issue 3, 1996, Pages 425-431

  Lip, Gregory Y H ^a,c   Lip, Peck Lin ^a   Zarifis, John ^a   Watson, Robert D S ^a   Bareford, David ^a   Lowe, Gordon D O ^b   Gareth Beevers, D ^a  

^a CITY HOSPITAL   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

anticoagulants; aspirin; fibrillation; fibrin; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA THROMBOGLOBULIN; FIBRIN; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM; STROKE; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; THROMBOGENESIS;

EID: 9444239741     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.3.425     Document Type: Article

References (25)

1. Lowe GDO. Antithrombotic treatment and atrial fibrillation. Br Med J. 1992;305:1445-1446.
2. Kumagai K, Fukunami M, Ohmori M, Kitabatake A, Kamada T, Hoki N. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol 1990;16:377-380.
3. Gustafsson C, Blomback M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke. 1990;21:47-51.
4. Lip GYH, Lowe GDO, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin therapy. Br Heart J. 1995;73:527-533.
5. Lip GYH, Lowe GDO. Fibrin D-dimer: a useful clinical marker of thrombogenesis? Clin Sci. 1995;89:205-214.
6. Hunt FA, Rylatt DB, Hart RA, Bundesen PG. Serum crosslinked fibrin (XDP) and fibrinogen/fibrin degradation products (FDP) in disorders associated with activation of the coagulation or fibrinolytic systems. Br J Haematol. 1985;60:715-722.
7. Islim I, Bareford D, Ebanks M, Beevers G. The role of platelets in essential hypertension. Blood Press. 1995;4:199-214.
8. Lip GYH, Rumley A, Dunn FG, Lowe GDO. Plasma fibrin D-dimer levels in patients with atrial fibrillation and left ventricular aneurysms: effects of introducing warfarin therapy on thrombogenesis. J Am Coll Cardiol. 1994;23:227A. Abstract.
9. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet. 1994;343: 687-691.
10. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med. 1994;154:1449-1457.
11. Lowe GDO, Rumley A, Yarnell JWG, Sweetnam PM, Thomas HF. Fibrin D-dimer, von Willebrand factor and tissue plasminogen activator antigens are predictors of major ischaemic heart disease: the Caerphilly Study. Blood Coagul Fibrinolysis. 1995;6:156-157.
12. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentrations of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation. 1994;90:2236-2240.
13. Fowkes FG, Lowe GDO, Housley E, Rattray A, Rumley A, Elton RA, MacGregor IR, Dawes J. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet. 1993;342:84-86.
14. Lip GYH, Tean KN, Dunn FG. Treatment of atrial fibrillation in a district general hospital. Br Heart J. 1994;71:92-95.
15. Bath PMW, Prasad A, Brown MM, MacGregor GA. Survey of use of anticoagulation in atrial fibrillation. Br Med J. 1993;307: 1045.
16. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;1:175-179.
17. Singer DE, Hughes RA, Gress DR, Sheehan MA, Oertel LB, Maraventano SW, Blewett DR, Rosner B, Kistler JP, for the BAATAF Investigators. The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: the BAATAF study. Am Heart J. 1992;124:1567-1573.
18. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation study: final results. Circulation. 1991;84: 527-539.
19. Bern MM, Lokich JJ, Wallach SR, Bothe A, Benotti PN, Arkin CF, Greco FA, Huberman M, Moore C. Very low doses of warfarin can prevent thrombosis in central venous catheters. Ann Intern Med. 1990;112:423-428.
20. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bramwell V, Pritchard KI, Stewart D, Goodwin P. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994;343:886-889.
21. Major ongoing stroke trials. Stroke. 1994;25:541-545.
22. Koenig W, Sund M, Lowe GDO, Lee AJ, Resch KL, Tunstall-Pedoe H, Keil U, Ernst E. Geographical variations in plasma viscosity and relation to coronary event rate. Lancet. 1994;344:711-714.
23. Lowe GDO. Blood rheology in arterial disease. Clin Sci. 1986;71: 137-146.
24. Lip GYH. Fibrinogen and cardiovascular disorders. QJM. 1995; 88:155-165.
25. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a metaanalysis and review of the literature. Ann Intern Med. 1993;118:956-963.